Droessler v. Wyeth-Ayerst Laboratories

64 F. Supp. 2d 1265, 1999 U.S. Dist. LEXIS 15062, 1999 WL 755962
CourtDistrict Court, S.D. Florida
DecidedAugust 4, 1999
Docket99-1870-Civ
StatusPublished
Cited by2 cases

This text of 64 F. Supp. 2d 1265 (Droessler v. Wyeth-Ayerst Laboratories) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Droessler v. Wyeth-Ayerst Laboratories, 64 F. Supp. 2d 1265, 1999 U.S. Dist. LEXIS 15062, 1999 WL 755962 (S.D. Fla. 1999).

Opinion

ORDER GRANTING PLAINTIFFS’ MOTION TO REMAND

JAMES LAWRENCE KING, District Judge.

THIS CAUSE comes before the Court on Plaintiffs Motion To Remand, filed July 13,1999.

I. Factual and Procedural Background

Plaintiff filed a Complaint in the Circuit Court of the Eleventh Judicial Circuit in and for Dade County, Florida on May 24, 1999. Plaintiff is a resident of Florida. See Am.Compl. at ¶ 2. Defendant Wyeth-Ayerst Laboratories (‘Wyeth-Ayerst”), a division of American Home Products Corporation (“American Home”), is a Delaware corporation with its principal place of business in New Jersey. See id. at ¶ 3. Defendant American Home is a Maryland Corporation with its principal place of business in New Jersey. See id. at ¶ 4. Defendant A.H. Robins Company, Inc. (“A.H.Robins”) is a Delaware corporation with its principal place of business in Virginia. See id. at ¶ 5. Defendant Eon Labs Manufacturing, Inc. (“Eon Labs”) is a Delaware corporation with its principal place of business in New York. See id. at ¶ 6. Defendant Walgreen Co. (“Walgreen”) is an Illinois corporation with its principal place of business in Illinois. See id. at ¶ 7. Defendant IVAX Corporation (“IVAX”) is a Florida corporation with its principal place of business in Florida. See id. at ¶ 8. Finally, Defendant Zenith Gold-line Pharmaceuticals, Inc. (“Zenith”), a wholly-owned subsidiary of IVAX, is a Florida corporation with its principal place of business in Florida. See id. at ¶ 10. Defendants allegedly are in the business of manufacturing, promoting, marketing, developing, supplying, labeling, testing, selling and/or distributing the pharmaceutical drugs fenfluramine (also known as Pondimin), dexfenfluramine hydrochloride (also known as Redux), and/or phenter-mine in the state of Florida. See id. at ¶¶ 3-10, 15.

The Food and Drug Administration (“FDA”) allegedly approved fenfluramine and phentermine separately for short-term weight reduction in obese patients. See id. at ¶ 18. Despite the fact that the FDA never approved the concomitant use of the two drugs, they allegedly have been prescribed and used in combination, commonly known as “fen-phen,” to maximize weight loss. See id. at ¶¶ 18-19. Plaintiff alleges that Defendants knew or should have known that Pondimin, Redux, and phentermine were causally related to and associated with severe and life-threatening complications and side effects, including pulmonary hypertension, cardiac valuvular disease and disorders, neurotoxicity, central and peripheral nervous system toxicity, brain serotonin neurotoxicity, cerebral' hemorrhage, ischemic stroke, neurocogni-tive dysfunction, and developmental neuro- *1268 toxicity. See id. at ¶ 20. Plaintiff avers that Defendants nevertheless distributed/sold the drugs without adequate warnings of the aforementioned complications and side effects, even though they knew or should have known that the drugs were being prescribed and used in a combination that had not been approved by the FDA. See id. at ¶¶ 21-22.

Plaintiff brings five tortious causes of . action against Defendants: (1) strict product liability for defective design, (2) strict product liability for failure to warn, (3) negligence, (4) breach of implied warranty, and (5) fraud and misrepresentation. See id. at ¶¶ 24-63. In addition, Plaintiff brings a sixth count alleging a conspiracy among the Defendants. See id. at ¶¶ 64-76. On June 22, 1999, Defendants Wyeth-Ayerst and American Home filed a Motion To Dismiss Plaintiffs Complaint, seeking dismissal of the counts alleging breach of warranty, fraud and misrepresentation, and conspiracy.

On July 2, 1999, Defendants Wyeth-Ayerst and American Home invoked 28 U.S.C. § 1441 to remove the above-styled matter to this Court. In representing to the Court that they had filed their Notice of Removal within 30 days after service of the state-court Complaint, Defendants Wyeth-Ayerst and American Home stated as follows:

Defendant AMERICAN HOME PRODUCTS CORPORATION was served with the Summons and Complaint on June 2, 1999. Defendant WALGREEN EASTERN CO., INC., upon information and belief, has not technically been served by virtue of an agreement between its counsel and plaintiffs counsel. Defendant IVAX CORPORATION, upon information and belief, has not yet been served. Defendant EON LABS MANUFACTURING, INC. was served on June 9,1999.

Notice of Removal, ¶ 1. Defendants Wyeth-Ayerst and American Home further asserted that Plaintiffs action originally could have been filed in federal court pursuant to 28 U.S.C. § 1332 because there is complete diversity between the parties and the amount in controversy is in excess of $75,000. See id. at ¶ 2. In asserting complete diversity, Defendants Wyeth-Ayerst and American Home argue that the joinder of Defendant IVAX, a Florida corporation, was fraudulent such that the right to removal remains. See id. at ¶¶ 9-11, citing Masepohl v. American Tobacco Co., Inc., 974 F.Supp. 1245, 1250 (D.Minn. 1997). In support of their contention that IVAX cannot be liable to Plaintiff under the causes of action stated, Defendants Wyeth-Ayerst and American Home provide an affidavit from Caterina Coloca, Associate General Counsel of IVAX (“Coloca affidavit”), in which she represents that IVAX “is a holding company which does not itself manufacture or distribute any pharmaceutical product.” See id. at Ex. 3, at ¶ 3. On July 19, 1999, Defendants Eon Labs and IVAX filed a Notice of Joinder in the Notice of Removal; Defendant Walgreen submitted a similar notice on July 30,1999.

On July 13, 1999, Plaintiff filed a Motion To Remand alleging that removal was improper on several grounds. First, Plaintiff maintains that, in order to be effective, the Notice of Removal had to have been filed on or before June 26,1999. See Pl.’s Mot., at 2-3. Second, Plaintiff contests the characterization that Defendant IVAX was fraudulently joined. See id. at 6-7. Third, Plaintiff asserts that the granting of Plaintiffs Motion For Leave To Amend, in which Plaintiff sought to add Defendant Zenith, would destroy complete diversity and therefore counsels against removal. See id. at 5-6. Finally, Plaintiff challenges the attempt of Defendants Wyeth-Ayerst and American Home to remove without obtaining written consents from other Defendants. See id. at 4-5. 1

*1269 On July 23, 1999, this Court entered an Order setting oral argument on Plaintiffs Motion To Remand for July 28, 1999. Claiming that they would be significantly prejudiced by having a hearing two days before their response to Plaintiffs Motion was due, Defendants Wyeth-Ayerst and American Home filed a Motion To Reset Oral Argument.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Williams v. Equifax Information Services LLC
359 F. Supp. 2d 1284 (M.D. Florida, 2005)
Pender v. Bell Asbestos Mines, Ltd.
145 F. Supp. 2d 1107 (E.D. Missouri, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
64 F. Supp. 2d 1265, 1999 U.S. Dist. LEXIS 15062, 1999 WL 755962, Counsel Stack Legal Research, https://law.counselstack.com/opinion/droessler-v-wyeth-ayerst-laboratories-flsd-1999.